Literature DB >> 22771326

Neurovascular protection conferred by 2-BFI treatment during rat cerebral ischemia.

Zhao Han1, Zhao-Hui Cheng, Shuang Liu, Jin-Long Yang, Mei-Juan Xiao, Rong-Yuan Zheng, Sheng-Tao Hou.   

Abstract

Stroke is caused by vascular dysfunction and currently there are no effective therapeutics to stroke induced brain damage. In contrast to an intense emphasis on neuroprotection, relatively few studies have addressed means of vascular protection in cerebral ischemia. Here we discovered that the ligand to immidazolin receptor, 2-BFI, not only provided potent neuroprotection during middle cerebral artery occlusion in rat, which confirmed our previous reports, but also protected the integrity of the cerebral vasculature. Treatment with 2-BFI twice daily after the occlusion of the middle cerebral artery for 14 d significantly improved the neurological deficits, reduced brain infarction, and importantly, protected the cerebral vasculature as evidenced by the increased expression of an endothelial marker, von Willebrand factor, and better preservation of the cerebral vasculature, as viewed under a confocal microscope on rat brain perfused with FITC-labeled dextran. These results indicated that 2-BFI contributes to protection of neurovasculature. Understanding the molecular mechanisms could eventually lead to development of more effective therapies for stroke. Crown
Copyright © 2012. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22771326     DOI: 10.1016/j.bbrc.2012.06.152

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

1.  Gender difference in epileptogenic effects of 2-BFI and BU224 in mice.

Authors:  Jia-Wei Min; Bi-Wen Peng; Xiaohua He; Yanan Zhang; Jun-Xu Li
Journal:  Eur J Pharmacol       Date:  2013-09-17       Impact factor: 4.432

2.  Brain protection conferred by long-term administration of 2-(2-benzofuranyl)-2-imidazoline against experimental autoimmune encephalomyelitis.

Authors:  Ying-Biao Zhu; Nian-Ge Xia; Yuan-Tao Zhang; Xin-Shi Wang; Shan-Shan Liang; Wei-Yong Yin; Hui-Qin Xu; Sheng-Tao Hou; Rong-Yuan Zheng
Journal:  Neurochem Res       Date:  2014-12-19       Impact factor: 3.996

Review 3.  Imidazoline I2 receptors: An update.

Authors:  Jun-Xu Li
Journal:  Pharmacol Ther       Date:  2017-03-16       Impact factor: 12.310

4.  I2-Imidazoline Ligand CR4056 Improves Memory, Increases ApoE Expression and Reduces BBB Leakage in 5xFAD Mice.

Authors:  Bibiana C Mota; Nathan Ashburner; Laura Abelleira-Hervas; Liyueyue Liu; Robertas Aleksynas; Lucio Claudio Rovati; Gianfranco Caselli; Magdalena Sastre
Journal:  Int J Mol Sci       Date:  2022-06-30       Impact factor: 6.208

5.  Fast, non-competitive and reversible inhibition of NMDA-activated currents by 2-BFI confers neuroprotection.

Authors:  Zhao Han; Jin-Long Yang; Susan X Jiang; Sheng-Tao Hou; Rong-Yuan Zheng
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

6.  Modulation of imidazoline I2 binding sites by CR4056 relieves postoperative hyperalgesia in male and female rats.

Authors:  Marco Lanza; Flora Ferrari; Ilaria Menghetti; Dario Tremolada; Gianfranco Caselli
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

7.  Combined Treatment With 2-(2-Benzofu-Ranyl)-2-Imidazoline and Recombinant Tissue Plasminogen Activator Protects Blood-Brain Barrier Integrity in a Rat Model of Embolic Middle Cerebral Artery Occlusion.

Authors:  Linlei Zhang; Shasha Xu; Xiaoxiao Wu; Jiaou Chen; Xiaoling Guo; Yungang Cao; Zheng Zhang; Jueyue Yan; Jianhua Cheng; Zhao Han
Journal:  Front Pharmacol       Date:  2020-06-12       Impact factor: 5.810

8.  2-(2-Benzofuranyl)-2-imidazoline treatment within 5 hours after cerebral ischemia/reperfusion protects the brain.

Authors:  Zheng Zhang; Jin-Long Yang; Lin-Lei Zhang; Zhen-Zhen Chen; Jia-Ou Chen; Yun-Gang Cao; Man Qu; Xin-Da Lin; Xun-Ming Ji; Zhao Han
Journal:  Neural Regen Res       Date:  2018-12       Impact factor: 5.135

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.